Sequencing treatment choices reduces the heterogeneity in the kinds of specific treatments patients receive, while retaining the locus of treatment decisions with the physician, not the study. An important feature of the PROSPECT kinase inhibitor Oligomycin A algorithm is that it is comprehensive, providing procedures for both the typical case and the atypical. At each step Inhibitors,research,lifescience,medical of the algorithm, physicians have the option of obtaining a consultation in psychiatry or referring a patient to a specialist with the expectation that upon completion of specialty care the patient will return to primary care. The

PROSPECT treatment algorithm recommends antidepressant therapy as first-line treatment with citalopram as the drug of choice. Citalopram was chosen because it is equally efficacious as other SSRIs and has an advantageous side-effect profile in use with the elderly. The study will provide citalopram to patients when prescribed by their physician. Physicians can consider other antidepressants if citalopram is contraindicated. If a patient does not want any antidepressant Inhibitors,research,lifescience,medical medication therapy, the physician can recommend psychotherapy. For the purposes of the study, the PROSPECT guideline recommends interpersonal therapy Inhibitors,research,lifescience,medical (IPT) and the study will provide IPT to patients for whom it is recommended. It may be helpful to reiterate that the purpose of PROSPECT is not to test whether or not citalopram

and IPT are efficacious in treating depression in elderly primary care patients. These therapies

were chosen because evidence already indicates that they Inhibitors,research,lifescience,medical can be effective under ideal conditions. Rather, the challenge of PROSPECT is to facilitate the efficacious use of these treatments under less than ideal conditions. Part of the goal is to ensure that physicians use these treatments Inhibitors,research,lifescience,medical in a recommended fashion. Research has also shown that when primary care physicians do follow practice guidelines, their use can positively influence both the process of care (93% of 59 studies) and clinical outcomes of care (81 % of 11 studies).39 Under normal circumstances, however, physicians are slow to adopt practice guidelines. Adoption of depression guidelines may face even greater barriers than guidelines for other conditions, as depression remains a stigmatized condition, especially in older GSK-3 cohorts. Thus, physicians can feel uncomfortable about giving their patients a diagnosis of depression and patients and family may not want to acknowledge one. Further, depression is not a focus of most primary care physicians’ training, so that some physicians consider it of secondary importance. Finally, comorbid medical illness, functional disability, and cognitive decline often complicate the diagnosis and treatment of depression and place competing demands on the physician and can make it more difficult for the patient to follow recommended treatment.